737 results on '"Wolf, Douglas C."'
Search Results
2. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)
3. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses
4. Surgery for Crohn’s Disease Is Associated With a Dysbiotic Microbiome and Metabolome: Results From Two Prospective Cohorts
5. A new paradigm for regulatory sciences
6. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
7. A new approach to the classification of carcinogenicity
8. Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need From the CorEvitas Inflammatory Bowel Disease Registry
9. Towards achieving a modern science-based paradigm for agrochemical carcinogenicity assessment
10. Assessing human carcinogenicity risk of agrochemicals without the rodent cancer bioassay
11. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
12. Rethinking chronic toxicity and carcinogenicity assessment for agrochemicals project (ReCAAP): A reporting framework to support a weight of evidence safety assessment without long-term rodent bioassays
13. Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
14. A Novel Approach to Integrate Human Biomonitoring Data with Model Predicted Dietary Exposures: A Crop Protection Chemical Case Study Using Lambda-Cyhalothrin
15. Surgery for Crohn’s Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts
16. A comprehensive view on mechanistic approaches for cancer risk assessment of non-genotoxic agrochemicals
17. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
18. An evaluation framework for new approach methodologies (NAMs) for human health safety assessment
19. Developing a modern approach to assess ecological risk from pesticides without unnecessary vertebrate animal testing.
20. S842 Pharmacokinetics, Exposure-Response Relationships, and Immunogenicity in Crohn’s Disease Patients With Ustekinumab Secondary Loss of Response Following Ustekinumab IV Re-Induction: Week 16 Results From the POWER Study
21. S1027 Impact of Prior Biologic Exposure on the Durability of 3-Year Continuous Ozanimod Treatment
22. S906 Efficacy and Durability of Ozanimod by Baseline Endoscopic Disease Activity in Advanced Therapy–Naive Ulcerative Colitis Patients Suboptimally Controlled on Conventional Therapies
23. S1067 Impact of Prior Biologic/Janus Kinase Inhibitor Therapy on the Efficacy of Etrasimod: Subgroup Analysis From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials
24. S1035 Analysis of Baseline Characteristics Associated With Clinical Response to Ustekinumab IV Re-Induction Strategy in Patients With Crohn’s Disease in the POWER Trial
25. S1134 Association of Nonswitched Memory B-Cell (MBC) Levels With Ozanimod (OZA) Efficacy in Patients (Pts) With Moderately to Severely Active Crohn’s Disease (CD): Results From the Phase 2 STEPSTONE Study
26. S911 Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
27. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)
28. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice
29. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
30. Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
31. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
32. Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
33. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
34. Developing Prototypes of a Modernized Approach to Assess Crop Protection Chemical Safety.
35. Long-term Safety of Ozanimod in Relapsing Multiple Sclerosis and Moderately to Severely Active Ulcerative Colitis (P7-3.007)
36. Is the 90-day dog study necessary for pesticide toxicity testing?
37. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
38. Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial
39. S732 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Moderate orSevere Endoscopic Disease Activity at Baseline: A Post Hoc Analysis of the Phase 3 True North Study
40. S734 Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12
41. Transforming the evaluation of agrochemicals
42. Dose and temporal effects on gene expression profiles of urothelial cells from rats exposed to diuron
43. Capsule Endoscopy Is Superior to Small-bowel Follow-through and Equivalent to Ileocolonoscopy in Suspected Crohn's Disease
44. Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned
45. Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
46. 885: TRIPLE COMBINATION THERAPY WITH VEDOLIZUMAB, ADALIMUMAB, AND METHOTREXATE IN PATIENTS WITH HIGH-RISK CROHN'S DISEASE: INTERIM ANALYSIS FROM THE OPEN-LABEL, PHASE 4 EXPLORER TRIAL
47. Tu1458: LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
48. 15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS
49. 653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION
50. Su1547: THE COMBINATION OF PATIENT REPORTED OUTCOMES AND THE ENDOSCOPIC HEALING INDEX IS A GOOD SURROGATE MARKER OF ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH CROHN'S DISEASE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.